Nivolumab

Where the papers sit

41 papers from the last 6 months study nivolumab directly · updated from PubMed 10 Oct 2026

• Real-World Nivolumab Outcomes

  Adjuvant nivolumab is being assessed in routine practice, especially after resection of stage III–IV melanoma, with survival and treatment-related toxicity as recurring endpoints. Real-world cohorts extend use to cancer of unknown primary and upper-tract urothelial cancer, while outcomes vary with stage and patient condition. Brain metastases, cachexia, probiotics and treatment discontinuation appear as potential modifiers. The set remains clinically heterogeneous rather than establishing one treatment strategy.

  10 papers · 24.4%

• Nivolumab in Lung Cancer

  Nivolumab-based immunotherapy is moving into perioperative and combination treatment for non-small cell lung cancer. Ipilimumab combinations are being evaluated across PD-L1–low metastatic disease, while chemotherapy is being added before surgery and TG4010 is being tested as a vaccine partner. Real-world work is testing rechallenge and treatment sequencing after progression, but early detriment signals and discontinuation concerns temper enthusiasm. Adjuvant benefit and the effects of COVID-19 vaccination and opioid use remain active questions.

  9 papers · 22%

• Immunotherapy in Kidney Cancer

  First-line metastatic renal cell carcinoma treatment is centered on nivolumab combinations with ipilimumab or tyrosine-kinase inhibitors such as cabozantinib. Studies are extending this approach to papillary and other non-clear cell disease, where evidence remains less established. Rechallenge and the timing of second-line nivolumab are being examined alongside progression-free survival, safety and prognostic scoring. Comparative effectiveness and cost analyses are increasingly shaping regimen selection.

  9 papers · 22%

• Combination Therapy in Liver Cancer

  Dual checkpoint and antiangiogenic strategies are being developed to overcome resistance in unresectable hepatocellular carcinoma. Lenvatinib with nivolumab and nivolumab with ipilimumab provide the main clinical approaches, including the CheckMate 9DW program. Nanoparticle delivery and exosome vaccines extend this strategy toward immune remodeling and tumor eradication in preclinical models. The field is moving from single-agent PD-1 blockade toward rational combinations, but clinical durability remains unsettled.

  7 papers · 17.1%

• Others — Immune-Related Toxicity

  Immune checkpoint treatment is repeatedly linked to uncommon inflammatory toxicities, including colitis, pancreatitis, folliculitis and pneumonitis with pneumomediastinum. These case reports emphasize organ-specific recognition and management of adverse events during prolonged nivolumab or combination therapy. The cluster also contains isolated reports of tumor responses in cholangiocarcinoma, gallbladder cancer and epithelioid angiomyolipoma. It therefore lacks a single direction beyond documenting the expanding clinical consequences of checkpoint blockade.

  6 papers · 14.6%